Teva Pharmaceutical Industries Ltd (TEVA) Expected to Post Earnings of $0.56 Per Share

Wall Street brokerages predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report earnings per share (EPS) of $0.56 for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with the lowest EPS estimate coming in at $0.43 and the highest estimate coming in at $0.68. Teva Pharmaceutical Industries posted earnings of $0.93 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 39.8%. The company is scheduled to report its next earnings report on Thursday, February 14th.

On average, analysts expect that Teva Pharmaceutical Industries will report full year earnings of $2.91 per share for the current fiscal year, with EPS estimates ranging from $2.77 to $3.03. For the next financial year, analysts anticipate that the business will post earnings of $2.80 per share, with EPS estimates ranging from $2.20 to $3.30. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a positive return on equity of 21.83% and a negative net margin of 54.67%. The firm had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.54 billion. During the same period in the prior year, the company earned $1.00 earnings per share. The company’s quarterly revenue was down 19.4% on a year-over-year basis.

TEVA has been the subject of several recent analyst reports. Mizuho upped their target price on Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the stock a “buy” rating in a research note on Monday, September 17th. Wells Fargo & Co set a $23.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Monday, September 17th. Jefferies Financial Group restated a “hold” rating and set a $21.00 target price on shares of Teva Pharmaceutical Industries in a research note on Friday, August 3rd. Bank of America upped their target price on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “underperform” rating in a research note on Friday, November 2nd. Finally, Cantor Fitzgerald set a $25.00 target price on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research note on Friday, September 14th. Four investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries presently has an average rating of “Hold” and a consensus price target of $21.58.

NYSE TEVA traded down $0.39 on Friday, hitting $23.45. 6,637,061 shares of the company’s stock were exchanged, compared to its average volume of 10,918,274. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 52 week low of $11.44 and a 52 week high of $25.96. The stock has a market capitalization of $24.13 billion, a PE ratio of 7.39, a PEG ratio of 7.28 and a beta of 0.77.

In related news, VP Richard Daniell sold 2,488 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the sale, the vice president now directly owns 2,488 shares in the company, valued at $58,940.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares of the company’s stock, valued at $56,334.96. The disclosure for this sale can be found here. Insiders have sold 6,531 shares of company stock valued at $152,749 over the last quarter. Company insiders own 0.43% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of TEVA. Dimensional Fund Advisors LP increased its holdings in Teva Pharmaceutical Industries by 16.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,185,541 shares of the company’s stock valued at $20,261,000 after purchasing an additional 168,658 shares during the period. Legal & General Group Plc increased its holdings in Teva Pharmaceutical Industries by 14.6% in the first quarter. Legal & General Group Plc now owns 611,919 shares of the company’s stock valued at $10,458,000 after purchasing an additional 77,766 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at $293,000. DnB Asset Management AS increased its holdings in Teva Pharmaceutical Industries by 13.6% in the second quarter. DnB Asset Management AS now owns 77,700 shares of the company’s stock valued at $1,890,000 after purchasing an additional 9,300 shares during the period. Finally, IFM Investors Pty Ltd increased its holdings in Teva Pharmaceutical Industries by 52.8% in the second quarter. IFM Investors Pty Ltd now owns 43,300 shares of the company’s stock valued at $1,053,000 after purchasing an additional 14,960 shares during the period. Institutional investors and hedge funds own 65.10% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: Growth Stocks

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply